Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.
The change—from “pass-through status” to “separately payable non-pass-through status”—meant that more drugs in 2019 than the year before were subject to the U.S. Centers for Medicare & Medicaid Services’ (CMS) nearly 30 percent reduction in Part B drug reimbursement for 340B disproportionate share hospitals, urban sole community hospitals, and rural referral centers.
Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
